FGI-106

FGI-106
	File:FGI-106 structure.png
Systematic (IUPAC) name
	1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine
Clinical data
Legal status	Investigational New Drug;
Identifiers
CAS Number	501081-38-5
PubChem	CID: 432342
ChemSpider	382357
Chemical data
Formula	C28H38N6
Molecular mass	458.640
	SMILES CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C ;
	InChI InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32) ; Key:WJUPENLNVUCETH-UHFFFAOYSA-N ;

FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses Hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus Dengue virus, and the filoviruses Ebola virus and Marburg virus.^[1]^[2]^[3]^[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.